• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Experimental Alzheimer’s Drug May Slow Memory Loss; Needs More Safety Study | Kaiser Health News


<











Coverage of this has given the company some desperately needed exposure. Maybe people won’t routinely mispronounce Eisai. They’re already backing away from market potential and who should use the therapy. Safety issues lion large. This will have modest impact and sales at the end of the day. Such is Eisai.